Cubist Systematic Strategies, LLC - ENANTA PHARMACEUTICALS INC ownership

ENANTA PHARMACEUTICALS INC's ticker is ENTA and the CUSIP is 29251M106. A total of 150 filers reported holding ENANTA PHARMACEUTICALS INC in Q3 2021. The put-call ratio across all filers is - and the average weighting 0.2%.

Quarter-by-quarter ownership
Cubist Systematic Strategies, LLC ownership history of ENANTA PHARMACEUTICALS INC
ValueSharesWeighting
Q3 2023$765,659
-64.4%
68,546
-31.8%
0.01%
-57.1%
Q2 2023$2,150,443
+46.6%
100,488
+177.0%
0.01%
+55.6%
Q1 2023$1,466,799
-9.5%
36,271
+4.2%
0.01%0.0%
Q4 2022$1,620,012
-22.6%
34,824
-13.6%
0.01%
-25.0%
Q3 2022$2,092,000
+18.3%
40,323
+7.7%
0.01%
+9.1%
Q2 2022$1,769,000
+491.6%
37,423
+791.9%
0.01%
+266.7%
Q1 2022$299,000
-91.5%
4,196
-91.0%
0.00%
-90.9%
Q4 2021$3,504,000
+440.7%
46,851
+310.5%
0.03%
+312.5%
Q3 2021$648,000
+222.4%
11,413
+180.3%
0.01%
+166.7%
Q1 2021$201,000
-69.3%
4,072
-71.6%
0.00%
-70.0%
Q3 2020$655,000
+31.5%
14,316
+44.3%
0.01%
+11.1%
Q2 2020$498,000
+69.4%
9,919
+73.8%
0.01%
+12.5%
Q1 2020$294,000
-40.7%
5,708
-28.8%
0.01%
-11.1%
Q4 2019$496,000
+47.6%
8,021
+43.5%
0.01%
+28.6%
Q3 2019$336,000
-18.8%
5,588
+14.0%
0.01%
-12.5%
Q2 2019$414,000
+16.3%
4,903
+31.5%
0.01%
-33.3%
Q1 2019$356,000
+51.5%
3,728
+12.3%
0.01%
+9.1%
Q4 2018$235,000
-56.5%
3,321
-28.7%
0.01%
-59.3%
Q2 2018$540,000
+14.2%
4,661
-20.3%
0.03%
-3.6%
Q1 2018$473,000
+75.2%
5,850
+27.0%
0.03%
+100.0%
Q4 2017$270,000
+2900.0%
4,607
+1435.7%
0.01%
+1300.0%
Q1 2017$9,0003000.00%
Other shareholders
ENANTA PHARMACEUTICALS INC shareholders Q3 2021
NameSharesValueWeighting ↓
Krensavage Asset Management, LLC 511,186$43,686,00011.23%
GREAT POINT PARTNERS LLC 210,400$17,981,0002.80%
ARMISTICE CAPITAL, LLC 456,000$38,970,0002.34%
Matarin Capital Management, LLC 210,208$17,964,376,0001.16%
Sapphire Star Partners LP 8,168$698,0000.70%
Granahan Investment Management 103,320$8,830,0000.48%
FARALLON CAPITAL MANAGEMENT LLC 867,500$74,137,0000.44%
361 CAPITAL LLC 19,040$1,627,0000.35%
ALGERT GLOBAL LLC 17,922$1,532,0000.33%
AlphaMark Advisors, LLC 9,310$796,0000.32%
View complete list of ENANTA PHARMACEUTICALS INC shareholders